The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

A method for inhibiting hair growth in mammals using compositions containing thiazoiidine or quinoline carboxamide FP receptor antagonists. The compositions can be applied topically to the skin and/or hair. The compositions can (1) arrest hirsutism or hypertrichosis, (2) reverse hirsutism, hypertrichosis, and/or unwanted hair, and (3) prevent or limit hair growth including after hair removal by chemical or physical methods. These compositions can also be used to help prevent or to limit the degree of hair loss from chemotherapy/cytotoxic chemical agents or radiation.

A method for inhibiting hair growth in mammals using compositions containing thiazoiidine or quinoline carboxamide FP receptor antagonists. The compositions can be applied topically to the skin and/or hair. The compositions can (1) arrest hirsutism or hypertrichosis, (2) reverse hirsutism, hypertrichosis, and/or unwanted hair, and (3) prevent or limit hair growth including after hair removal by chemical or physical methods. These compositions can also be used to help prevent or to limit the degree of hair loss from chemotherapy/cytotoxic chemical agents or radiation.

The present disclosure relates to a recombinant collagen fragment having a molecular weight of about 55 kDa, and compositions comprising the recombinant collagen fragment. Methods of producing the recombinant collagen fragment and methods of treatment using the recombinant collagen fragment are also provided.

The present invention relates to extracts of Isochrysis sp., preferably Tahitian Isochrysis, its cosmetic, dermatological and/or therapeutic uses and compositions and cosmetic, dermatological or therapeutic products comprising such an extract of Isochrysis sp., preferably Tahitian Isochrysis.

The present invention relates to extracts of Isochrysis sp., preferably Tahitian Isochrysis, its cosmetic, dermatological and/or therapeutic uses and compositions and cosmetic, dermatological or therapeutic products comprising such an extract of Isochrysis sp., preferably Tahitian Isochrysis.

The present invention provides a peptide having skin-whitening activity. The peptide of the present invention exhibits an excellent skin whitening effect by inhibiting melanogenesis, inhibiting the activity of tyrosinase, inhibiting the expression of melanosis-involved factors, and inhibiting melanosome transfer. The peptide of the present invention has excellent skin permeability due to the small size thereof. Excellent activity and stability of the foregoing peptide of the present invention can be very favorably applied to cosmetics.

The present invention provides a peptide having skin-whitening activity. The peptide of the present invention exhibits an excellent skin whitening effect by inhibiting melanogenesis, inhibiting the activity of tyrosinase, inhibiting the expression of melanosis-involved factors, and inhibiting melanosome transfer. The peptide of the present invention has excellent skin permeability due to the small size thereof. Excellent activity and stability of the foregoing peptide of the present invention can be very favorably applied to cosmetics.

A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.